Cannabis UseNCT05521321

Feasibility and Acceptability of the Cannabis Awareness and Prevention Toolkit

A study testing Stanford Smart Talk Cannabis Awareness and Prevention curriculum in people with Cannabis Use, run by Stanford University at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

Who is it for?: Ages 10 to 20 yearsHealthy volunteers can take part
Conditions the study is for: Cannabis Use
What is being tested?: Stanford Smart Talk Cannabis Awareness and Prevention curriculum
Type of treatment: Lifestyle or therapy programme
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 658 participants
Where: 1 siteUnited States
Study dates: 1 Oct 2022to 16 May 2025
Phase: Interventional
Are there results?: Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 10 to 20 years
All sexes
Healthy volunteers accepted
Child, Adult

Who may be able to join

Middle school and high school students receiving health education at schools participating in the study

Who cannot join

Trial locations and contacts

1 site in 1 country.

United States1 site

Stanford University
Palo Alto, California, 94304

Other trials in United States

About this study

The Stanford Smart Talk Cannabis Awareness and Prevention Curriculum includes 5 lessons, each providing activities, online quiz games, and worksheets in addition to presentations, resources, and other materials aimed at addressing key factors associated with youth cannabis use, including changing adolescents' attitudes towards and misperceptions about cannabis; increasing their refusal skills to pulls of marketing and social media; reducing stress and depression which have been linked to cannabis initiation and use; improving coping skills; and decreasing intentions and actual use of all cannabis products.

The aim of this study is to investigate the extent to which the curriculum changes students' intentions to use and actual use of cannabis.

Conditions: Cannabis Use
Being tested: Stanford Smart Talk Cannabis Awareness and Prevention curriculum
Keywords: youth, cannabis, education, health, prevention, marijuana
Medical subject headings: Marijuana Abuse

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Stanford Smart Talk Cannabis Awareness and Prevention curriculumBehavioural
Stanford Cannabis Awareness and Prevention curriculum delivered as a 5-session curriculum administered in a school classroom setting.

Study groups in NCT05521321
Study group	Role	What they receive
Receives the Stanford Smart Talk Cannabis Prevention and Awareness curriculum	Experimental	Stanford Smart Talk Cannabis Prevention and Awareness curriculum administered Receives: Behavioral: Stanford Smart Talk Cannabis Awareness and Prevention curriculum
Does not receive Stanford Smart Talk Cannabis Prevention and Awareness curriculum	No intervention	Receives another curriculum or no cannabis prevention curriculum

What is being measured

The primary outcome is the main question the study is designed to answer.

Cannabis Use (Lifetime)
Investigator-originated survey measures (questions) assess lifetime cannabis use. This outcome measure assesses cannabis use.
Measured: Baseline, Post-intervention (approx. 3 days post-baseline), and 6-month Follow-up
Cannabis Use (Past 30 Days)
Investigator-originated survey measures (questions) assess cannabis use in the past 30 days.
Measured: Baseline, Post-intervention (approx. 3 days post-baseline), and 6-month Follow-up
Intention to Use Cannabis in the Future - Smoked Cannabis
Investigator-originated survey measures (questions) assessing participant intention to use cannabis in the future. Assessed on a Likert-scale (1 - Definitely not, 4 - Definitely yes).
Measured: Baseline, Post-intervention (approx. 3 days post-baseline), and 6-month Follow-up
Intention to Use Cannabis in the Future - Vaped Cannabis
Investigator-originated survey measures (questions) assessing participant intention to use cannabis in the future. Assessed on a Likert-scale (1 - Definitely not, 4 - Definitely yes).
Measured: Baseline, Post-intervention (approx. 3 days post-baseline), and 6-month Follow-up
Intention to Use Cannabis in the Future - Cannabis Edibles
Investigator-originated survey measures (questions) assessing participant intention to use cannabis in the future. Assessed on a Likert-scale (1 - Definitely not, 4 - Definitely yes).
Measured: Baseline, Post-intervention (approx. 3 days post-baseline), and 6-month Follow-up

Secondary outcomes (4)

Cannabis Knowledge
Participants were asked 13 questions related to their knowledge of cannabis, resulting in an overall scale of 0 to 13, higher scores indicated greater knowledge.
Measured: Baseline and Post-intervention (approx. 3 days post-baseline)
Perceived Addictiveness and Harmfulness - Smoked Cannabis
Investigator-originated survey measures (questions) assessing participants' perceptions of cannabis addiction and harm. Assessed on a Likert-scale (1 - Not at all addictive/harmful, 5 - Extremely addictive/harmful).
Measured: Baseline, Post-intervention (approx. 3 days post-baseline), and 6-month Follow-up
Perceived Addictiveness and Harmfulness - Vaped Cannabis
Investigator-originated survey measures (questions) assessing participants' perceptions of cannabis addiction and harm. Assessed on a Likert-scale (1 - Not at all addictive/harmful, 5 - Extremely addictive/harmful).
Measured: Baseline, Post-intervention (approx. 3 days post-baseline), and 6-month Follow-up
Perceived Addictiveness and Harmfulness - Cannabis Edibles
Investigator-originated survey measures (questions) assessing participants' perceptions of cannabis addiction and harm. Assessed on a Likert-scale (1 - Not at all addictive/harmful, 5 - Extremely addictive/harmful).
Measured: Baseline, Post-intervention (approx. 3 days post-baseline), and 6-month Follow-up

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

1 Oct 202216 May 2025

First posted30 Aug 2022
Study start1 Oct 2022
Primary completion16 May 2025
Study completion16 May 2025

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
Other trials for Cannabis UseStudies of the same condition, open and under way.
More trials run by Stanford UniversityThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase N/A
Primary purpose: Prevention
Allocation: Randomised
Intervention model: Parallel groups
Masking: None (open label)
Enrolment: 658 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT05521321
Sponsor's protocol ID: 58068
Other IDs: 1R34DA053704
Status last verified: Jun 2026
First submitted: 26 Aug 2022
Last updated: 28 Jul 2026
Results posted: Yes, on ClinicalTrials.gov
Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No
Individual data sharing: No

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Not yet recruiting
Substance Use and Media Preferences
Substance Use Behavior, Cannabis Intoxication
RecruitingObservational study
Study of an Oral Fluid Testing Approach
Cannabis Use, Cannabis Intoxication
Active, not recruitingPhase 1
Psilocybin-assisted Treatment for Cannabis Use Disorder
Cannabis Use Disorder
RecruitingObservational study
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Breast Carcinoma, Colorectal Carcinoma
Not yet recruitingEarly Phase 1
Lung Health and Breath Biomarkers: Acute Effects of Inhaled Cannabis
Cannabis Use, Tobacco

All Cannabis Use trials

Study at a glance

From the registry record, last updated by the sponsor on 28 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: Feasibility and Acceptability of the Cannabis Awareness and Prevention Toolkit
ClinicalTrials.gov ID: NCT05521321
Acronym / sponsor ID: 58068
Conditions: Cannabis Use
Keywords: youth, cannabis, education, health, prevention, marijuana
Study type: Interventional
Recruitment status: Completed
Enrolment: 658 participants (actual)
Lead sponsor: Stanford UniversityUniversity, hospital or other
Collaborators: National Institute on Drug Abuse (NIDA)
Study start: 1 Oct 2022 (actual)
Primary completion: 16 May 2025 (actual)
Study completion: 16 May 2025 (actual)
First posted: 30 Aug 2022 (actual)
Results: Posted 28 Jul 2026

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

The aim of this study is to investigate the extent to which the curriculum changes students' intentions to use and actual use of cannabis.

Study design

Primary purpose: Prevention
Allocation: Randomised
Intervention model: Parallel groups
Masking: None (open label)
Number of arms: 2

Arm	Type	Receives
Receives the Stanford Smart Talk Cannabis Prevention and Awareness curriculum	Experimental	Behavioral: Stanford Smart Talk Cannabis Awareness and Prevention curriculumStanford Smart Talk Cannabis Prevention and Awareness curriculum administered
Does not receive Stanford Smart Talk Cannabis Prevention and Awareness curriculum	No intervention	–Receives another curriculum or no cannabis prevention curriculum

Who may qualify

Ages: 10 to 20 years
Sex: All
Healthy volunteers: Accepted
Age groups: Child, Adult

Key inclusion criteria (1 listed)

Middle school and high school students receiving health education at schools participating in the study

Key exclusion criteria (1 listed)

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
Stanford Smart Talk Cannabis Awareness and Prevention curriculumStanford Cannabis Awareness and Prevention curriculum delivered as a 5-session curriculum administered in a school classroom setting.	Behavioural	Receives the Stanford Smart Talk Cannabis Prevention and Awareness curriculum

Primary outcome

Cannabis Use (Lifetime)
Time frame: Baseline, Post-intervention (approx. 3 days post-baseline), and 6-month Follow-up
Investigator-originated survey measures (questions) assess lifetime cannabis use. This outcome measure assesses cannabis use.
Cannabis Use (Past 30 Days)
Time frame: Baseline, Post-intervention (approx. 3 days post-baseline), and 6-month Follow-up
Investigator-originated survey measures (questions) assess cannabis use in the past 30 days.
Intention to Use Cannabis in the Future - Smoked Cannabis
Time frame: Baseline, Post-intervention (approx. 3 days post-baseline), and 6-month Follow-up
Investigator-originated survey measures (questions) assessing participant intention to use cannabis in the future. Assessed on a Likert-scale (1 - Definitely not, 4 - Definitely yes).
Intention to Use Cannabis in the Future - Vaped Cannabis
Time frame: Baseline, Post-intervention (approx. 3 days post-baseline), and 6-month Follow-up
Investigator-originated survey measures (questions) assessing participant intention to use cannabis in the future. Assessed on a Likert-scale (1 - Definitely not, 4 - Definitely yes).
Intention to Use Cannabis in the Future - Cannabis Edibles
Time frame: Baseline, Post-intervention (approx. 3 days post-baseline), and 6-month Follow-up
Investigator-originated survey measures (questions) assessing participant intention to use cannabis in the future. Assessed on a Likert-scale (1 - Definitely not, 4 - Definitely yes).

4 secondary outcomes

Cannabis Knowledge
Time frame: Baseline and Post-intervention (approx. 3 days post-baseline)
Perceived Addictiveness and Harmfulness - Smoked Cannabis
Time frame: Baseline, Post-intervention (approx. 3 days post-baseline), and 6-month Follow-up
Perceived Addictiveness and Harmfulness - Vaped Cannabis
Time frame: Baseline, Post-intervention (approx. 3 days post-baseline), and 6-month Follow-up
Perceived Addictiveness and Harmfulness - Cannabis Edibles
Time frame: Baseline, Post-intervention (approx. 3 days post-baseline), and 6-month Follow-up

Results and safety

Results posted to the registry on 28 Jul 2026, as reported by the sponsor. Figures are copied from the record, not re-analysed. Full results on ClinicalTrials.gov.

Participant flow

Group	Started	Completed
Receives the Stanford Cannabis Prevention and Awareness Curriculum	427	304
Does Not Receive Stanford Cannabis Prevention and Awareness Curriculum	239	144

Primary outcome: Cannabis Use (Lifetime)

Time frame: Baseline, Post-intervention (approx. 3 days post-baseline), and 6-month Follow-up. Count of participants. Unit: Participants

Measure	Receives the Stanford Cannabis Prevention and Awareness Curriculum n = 127	Does Not Receive Stanford Cannabis Prevention and Awareness Curriculum n = 137
Baseline	13	10
Post-intervention (approx. 3 days post-baseline)	13	13
6-month Follow-up	15	21

Population analysed: Students from middle schools who received the allocated intervention and responded to the survey at the respective time points.

Primary outcome: Cannabis Use (Past 30 Days)

Time frame: Baseline, Post-intervention (approx. 3 days post-baseline), and 6-month Follow-up. Count of participants. Unit: Participants

Measure	Receives the Stanford Cannabis Prevention and Awareness Curriculum n = 15	Does Not Receive Stanford Cannabis Prevention and Awareness Curriculum n = 21
Baseline	8	3
Post-intervention (approx. 3 days post-baseline)	8	4
6-month Follow-up	11	11

Population analysed: Students from middle schools who reported any lifetime cannabis use, received the allocated intervention, and responded to the survey at the respective time points.

Primary outcome: Intention to Use Cannabis in the Future - Smoked Cannabis

Time frame: Baseline, Post-intervention (approx. 3 days post-baseline), and 6-month Follow-up. Mean (Standard Deviation). Unit: score on a scale

Measure	Receives the Stanford Cannabis Prevention and Awareness Curriculum n = 127	Does Not Receive Stanford Cannabis Prevention and Awareness Curriculum n = 136
Baseline - Ever-Users	2.71 (0.95)	3.67 (0.58)
Post-intervention (approx. 3 days post-baseline) - Ever-Users	2.57 (1.13)	2.44 (1.42)
6-month Follow-up - Ever-Users	3.08 (0.52)	3.58 (0.67)
Baseline - Never-Users	1.85 (0.95)	1.92 (0.99)
Post-intervention (approx. 3 days post-baseline) - Never-Users	1.78 (0.92)	1.85 (0.95)
6-month Follow-up - Never-Users	1.92 (0.95)	1.88 (1.0)

Population analysed: Students from middle schools who received the allocated intervention and responded to the survey at the respective time points.

Primary outcome: Intention to Use Cannabis in the Future - Vaped Cannabis

Time frame: Baseline, Post-intervention (approx. 3 days post-baseline), and 6-month Follow-up. Mean (Standard Deviation). Unit: score on a scale

Measure	Receives the Stanford Cannabis Prevention and Awareness Curriculum n = 126	Does Not Receive Stanford Cannabis Prevention and Awareness Curriculum n = 136
Baseline - Ever-Users	2.67 (0.87)	2.6 (1.34)
Post-intervention (approx. 3 days post-baseline) - Ever-Users	2.7 (0.95)	2.4 (1.35)
6-month Follow-up - Ever-Users	2.75 (1.04)	2.94 (1.06)
Baseline - Never-Users	1.46 (0.65)	1.61 (0.73)
Post-intervention (approx. 3 days post-baseline) - Never-Users	1.43 (0.68)	1.56 (0.71)
6-month Follow-up - Never-Users	1.5 (0.74)	1.56 (0.73)

Population analysed: Students from middle schools who received the allocated intervention and responded to the survey at the respective time points.

4 secondary outcomes are reported in the full results.

Adverse events

Time frame: Up to 9 months.. Other adverse events reported at 0% frequency or more

Group	Serious adverse events	Other adverse events	Deaths
Receives the Stanford Cannabis Prevention and Awareness Curriculum	0 of 419 (0%)	0 of 419 (0%)	0 of 419
Does Not Receive Stanford Cannabis Prevention and Awareness Curriculum	0 of 239 (0%)	0 of 239 (0%)	0 of 239

Loading the posted results from ClinicalTrials.gov…

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 28 Jul 2026.
Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Link to Stanford Smart Talk Cannabis Awareness and Prevention CurriculumLink provided by the sponsor.
Individual participant dataSharing planned: No

Related trials for Cannabis Use

Not yet recruiting
Substance Use and Media Preferences
Substance Use Behavior, Cannabis Intoxication
RecruitingObservational study
Study of an Oral Fluid Testing Approach
Cannabis Use, Cannabis Intoxication
Active, not recruitingPhase 1
Psilocybin-assisted Treatment for Cannabis Use Disorder
Cannabis Use Disorder
RecruitingObservational study
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Breast Carcinoma, Colorectal Carcinoma
Not yet recruitingEarly Phase 1
Lung Health and Breath Biomarkers: Acute Effects of Inhaled Cannabis
Cannabis Use, Tobacco

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

Bonnie Halpern-Felsher, Ph.D. principal investigator

Stanford University

1 site in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A study testing Stanford Smart Talk Cannabis Awareness and Prevention curriculum in people with Cannabis Use, run by Stanford University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 28 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 28 Jul 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Cannabis Use (Lifetime) (time frame: Baseline, Post-intervention (approx. 3 days post-baseline), and 6-month Follow-up). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05521321.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Jul 2026.